Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers

AIDS Research and Human Retroviruses

Volumn 30, Issue 7, 2014, Pages 654-664

  Tandon, Ravi ^a   Chew, Glen M ^a   Byron, Mary M ^a   Borrow, Persephone ^b   Niki, Toshiro ^c   Hirashima, Mitsuomi ^c   Barbour, Jason D ^a   Norris, Philip J ^d,e   Lanteri, Marion C ^d   Martin, Jeffrey N ^e   Deeks, Steven G ^e   Ndhlovu, Lishomwa C ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KAGAWA UNIVERSITY   (Japan)

^d BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ECALECTIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; PROTEIN TIM 3; RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA; ANTIRETROVIRUS AGENT; GALECTIN; HAVCR2 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; LGALS9 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN DISULFIDE ISOMERASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; BLOOD; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GALECTINS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; INTERLEUKIN-1BETA; MEMBRANE PROTEINS; PROTEIN DISULFIDE-ISOMERASES; RNA, VIRAL; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903791964     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0004     Document Type: Article

References (92)

1. UNAIDS: How to get to zero: Faster, smarter, better. World AIDS day report, 2011. www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2011/JC2216-WorldAIDSday-report-2011-en.pdf.AccessedFebruary1, 2012.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853860.
3. Robertson KR, Smurzynski M, Parsons TD, et al.: The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21(14):19151921.
4. Bini EJ, Park J, and Francois F: Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006; 166(15):16261631.
5. Deeks SG and Phillips AN: HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:a3172.
6. Ances BM, Vaida F, Yeh MJ, et al.: HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis 2010; 201(3):336340.
7. Currier JS, Lundgren JD, Carr A, et al.: Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118(2):e2935.
8. Triant VA, Lee H, Hadigan C, and Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92(7):25062512.
9. Kirk GD, Merlo C, P OD, et al.: HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007;45(1):103110.
10. Okulicz JF and Lambotte O: Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS 2011;6(3):163168.
11. Krishnan S, Wilson EM, Sheikh V, et al.: Evidence for innate immune system activation in HIV Type 1-infected elite controllers. J Infect Dis 2014;209(6):931939.
12. Appay V and Sauce D: Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol 2008;214(2):231241.
13. Highleyman L: Inflammation, immune activation, and HIV. BETA Bull Exp Treat AIDS 2010;22(2):1226.
14. Butler SL, Valdez H, Westby M, et al.: Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2011; 58(3):297303.
15. Neuhaus J, Jacobs DR Jr, Baker JV, et al.: Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;201(12): 17881795.
16. Burdo TH, Lentz MR, Autissier P, et al.: Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011;204(1):154163.
17. French MA, King MS, Tschampa JM, et al.: Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4 + T cells. J Infect Dis 2009;200(8):1212 1215.
18. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):13651371.
19. Sandler NG, Wand H, Roque A, et al.: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203(6):780790.
20. Hunt PW, Cao HL, Muzoora C, et al.: Impact of CD8 + Tcell activation on CD4 + T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011;25(17):21232131.
21. Levy Y, Lacabaratz C, Weiss L, et al.: Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009;119(4):9971007.
22. Sereti I, Dunham RM, Spritzler J, et al.: IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009;113(25):63046314.
23. Behler CM, Vittinghoff E, Lin F, et al.: Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis 2007; 44(10):13751383.
24. Lugli E, Mueller YM, Lewis MG, et al.: IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques. Blood 2011;118(9):25202529.
25. Gringeri A, Musicco M, Hermans P, et al.: Active antiinterferon- alpha immunization: A European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(4):358370.
26. Crawford TQ, Ndhlovu LC, Tan A, et al.: HIV-1 infection abrogates CD8 + T cell mitogen-activated protein kinase signaling responses. J Virol 2011;85(23):1234312350.
27. Capini CJ, Richardson MW, Hendel H, et al.: Autoantibodies to TNFalpha in HIV-1 infection: Prospects for anti-cytokine vaccine therapy. Biomed Pharmacother 2001; 55(1):2331.
28. Cepeda EJ, Williams FM, Ishimori ML, et al.: The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67(5):710712.
29. Westlake SL, Colebatch AN, Baird J, et al.: The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology 2010;49(2):295307.
30. Takamura S, Tsuji-Kawahara S, Yagita H, et al.: Premature terminal exhaustion of Friend virus-specific effector CD8 + T cells by rapid induction of multiple inhibitory receptors. J Immunol 2010;184(9):46964707.
31. Hafler DA and Kuchroo V: TIMs: Central regulators of immune responses. J Exp Med 2008;205(12):26992701.
32. Jin HT, Anderson AC, Tan WG, et al.: Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010;107(33): 1473314738.
33. Jones RB, Ndhlovu LC, Barbour JD, et al.: Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205(12):27632779.
34. Vali B, Jones RB, Sakhdari A, et al.: HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010;40(9):24932505.
35. Blackburn SD, Shin H, Haining WN, et al.: Coregulation of CD8 + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10(1): 2937.
36. Wherry EJ, Ha SJ, Kaech SM, et al.: Molecular signature of CD8 + T cell exhaustion during chronic viral infection. Immunity 2007;27(4):670684.
37. Bengsch B, Seigel B, Ruhl M, et al.: Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8 + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 2010;6(6):e1000947.
38. Nakanjako D, Ssewanyana I, Mayanja-Kizza H, et al.: High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011;11:43.
39. Sauce D, Larsen M, Fastenackels S, et al.: HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 2011; 117(19):51425151.
40. Wada J and Kanwar YS: Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 1997;272(9):60786086.
41. Anderson AC, Anderson DE, Bregoli L, et al.: Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007;318(5853): 11411143.
42. Dai SY, Nakagawa R, Itoh A, et al.: Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 2005;175(5):29742981.
43. Nagahara K, Arikawa T, Oomizu S, et al.: Galectin-9 increases Tim-3 + dendritic cells and CD8 + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 2008;181(11):76607669.
44. Jayaraman P, Sada-Ovalle I, Beladi S, et al.: Tim3 binding to galectin-9 stimulates antimicrobial immunity. J Exp Med 2010;207(11):23432354.
45. Zhu C, Anderson AC, Schubart A, et al.: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6(12):12451252.
46. Arikawa T, Saita N, Oomizu S, et al.: Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol 2010;40(2):548558.
47. Oomizu S, Arikawa T, Niki T, et al.: Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3- independent manner. Clin Immunol 2012;143(1):5158.
48. Seki M, Oomizu S, Sakata KM, et al.: Galectin-9 suppresses the generation of Th17, promotes the induction ofregulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008;127(1):7888.
49. Irie A, Yamauchi A, Kontani K, et al.: Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005;11(8):29622968.
50. Imaizumi T, Kumagai M, Sasaki N, et al.: Interferongamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol 2002;72(3):486491.
51. Mengshol JA, Golden-Mason L, Arikawa T, et al.: A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One 2010;5(3):e9504.
52. Wiener Z, Kohalmi B, Pocza P, et al.: TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 2007;127(4):906914.
53. Wang F, Wan L, Zhang C, et al.: Tim-3-galectin-9 pathway involves the suppression induced by CD4 + CD25 + regulatory T cells. Immunobiology 2009;214(5):342349.
54. Hastings WD, Anderson DE, Kassam N, et al.: TIM-3 is expressed on activated human CD4( + ) T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 2009;39(9): 24922501.
55. Qiu Y, Chen J, Liao H, et al.: Tim-3-expressing CD4( + ) and CD8( + ) T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti- TB effector functions. PLoS Pathog 2012;8(11):e1002984.
56. Oomizu S, Arikawa T, Niki T, et al.: Cell surface galectin-9 expressing th cells regulate th17 and foxp3( + ) treg development by galectin-9 secretion. PloS One 2012;7(11):e48574.
57. Niki T, Tsutsui S, Hirose S, et al.: Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J Biol Chem 2009;284(47):3234432352.
58. Bi S, Hong PW, Lee B, and Baum LG: Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci USA 2011;108(26):1065010655.
59. Sharma S, Sundararajan A, Suryawanshi A, et al.: T cell immunoglobulin and mucin protein-3 (Tim-3)/galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci USA 2011; 108(47):1900119006.
60. Sehrawat S, Reddy PB, Rajasagi N, et al.: Galectin-9/TIM- 3 interaction regulates virus-specific primary and memory CD8 T cell response. PLoS Pathog 2010;6(5):e1000882.
61. Rangachari M, Zhu C, Sakuishi K, et al.: Bat3 promotes T cell responses and autoimmunity by repressing Tim-3- mediated cell death and exhaustion. Nat Med 2012;18(9): 13941400.
62. Clayton KL, Haaland MS, Douglas-Vail MB, et al.: T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases. J Immunol 2014; 19(2):782791.
63. Tandon R, Giret MT, Sengupta D, et al.: Age-related expansion of Tim-3 expressing T cells in vertically HIV-1 infected children. PloS One 2012;7(9):e45733.
64. Elahi S, Dinges WL, Lejarcegui N, et al.: Protective HIVspecific CD8 + T cells evade Treg cell suppression. Nat Med 2011;17(8):989995.
65. Chagan-Yasutan H, Saitoh H, Ashino Y, et al.: Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. Tohoku J Exp Med 2009;218(4):285292.
66. Jost S, Moreno-Nieves UY, Garcia-Beltran WF, et al.: Dysregulated Tim-3 expression on natural killer cells is associated with increased galectin-9 levels in HIV-1 infection. Retrovirology 2013;10:74.
67. Elahi S, Niki T, Hirashima M, and Horton H: Galectin-9 binding to Tim-3 renders activated human CD4 + T cells less susceptible to HIV-1 infection. Blood 2012;119(18): 41924204.
68. Stacey AR, Norris PJ, Qin L, et al.: Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009;83(8): 37193733.
69. Leitner J, Rieger A, Pickl WF, et al.: TIM-3 does not act as a receptor for galectin-9. PLoS Pathog 2013;9(3):e1003253.
70. Jones RB, Ndhlovu LC, Barbour JD, et al.: Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205(12):27632779.
71. Haase AT: Perils at mucosal front lines for HIV and SIV and their hosts. Nature reviews. Immunology 2005;5(10): 783792.
72. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4 + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200(6):749759.
73. Herbeuval JP, Hardy AW, Boasso A, et al.: Regulation of TNF-related apoptosis-inducing ligand on primary CD4 + T cells by HIV-1: Role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005; 102(39):1397413979.
74. Wiersma VR, de Bruyn M, Helfrich W, and Bremer E: Therapeutic potential of galectin-9 in human disease. Med Res Rev 2013;33(Suppl 1):E102126.
75. Kared H, Fabre T, Bedard N, et al.: Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013;9(6):e1003422.
76. Ndhlovu LC, Sinclair E, Epling L, et al.: IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4 + T (T(H)17) cells in the periphery. J Clin Immunol 2010;30(5):681692.
77. Ndhlovu LC, Loo CP, Spotts G, et al.: FOXP3 expressing CD127lo CD4 + T cells inversely correlate with CD38 + CD8 + T cell activation levels in primary HIV-1 infection. J Leuk Biol 2008;83(2):254262.
78. Ndhlovu LC, Chapman JM, Jha AR, et al.: Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS 2008;22(8): 990992.
79. Pasternak AO, Jurriaans S, Bakker M, et al.: Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 2009;4(12):e8490.
80. Lambotte O, Boufassa F, Madec Y, et al.: HIV controllers: A homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005;41(7):10531056.
81. Petrovas C, Mueller YM, and Katsikis PD: Apoptosis of HIV-specific CD8 + T cells: An HIV evasion strategy. Cell Death Differ 2005;12(Suppl 1):859870.
82. Yan J, Sabbaj S, Bansal A, et al.: HIV-specific CD8 + T cells from elite controllers are primed for survival. J Virol 2013;87(9):51705181.
83. Sajadi MM, Constantine NT, Mann DL, et al.: Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr 2009;50(4): 403408.
84. Hunt PW, Brenchley J, Sinclair E, et al.: Relationship between T cell activation and CD4 + T cell count in HIVseropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197(1):126133.
85. Hsue PY, Deeks SG, Farah HH, et al.: Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008;22(7):825833.
86. Pereyra F, Palmer S, Miura T, et al.: Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009;200(6):984990.
87. Hatano H, Delwart EL, Norris PJ, et al.: Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009;83(1):329335.
88. Hunt PW, Landay AL, Sinclair E, et al.: A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 2011;6(1):e15924.
89. Hunt PW, Brenchley J, Sinclair E, et al.: Relationship between T cell activation and CD4 + T cell count in HIVseropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197(1):126133.
90. Shasha D and Walker BD: Lessons to be learned from natural control of HIVFuture directions, therapeutic, and preventive implications. Front Immunol 2013;4:162.
91. Doitsh G, Cavrois M, Lassen KG, et al.: Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010;143(5):789801.
92. Doitsh G, Galloway NL, Geng X, et al.: Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014;505(7484):509514.